Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (stock symbol: REVB) is a clinical-stage life sciences company dedicated to advancing immunologic therapeutics and diagnostics designed to improve global health. At the core of its innovative endeavors is Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), an established TLR4 agonist. This formulation is designed to stimulate the body's innate immune response to prevent and treat various diseases.
The company is actively developing a pipeline of high-value product candidates based on this unique Gemini formulation. These programs include:
- Gemini-SSI: Focused on preventing surgical site infections (SSI).
- Gemini-AKI: Aimed at preventing acute kidney injury (AKI).
- Gemini-CKD: Targeted at treating chronic kidney disease (CKD).
Revelation Biosciences, Inc. is committed to leveraging the science of trained immunity through the Gemini-based products to address significant unmet medical needs and improve patient outcomes. The company continues to make strides in their clinical trials and research, aiming for groundbreaking advancements in healthcare.
With a strong focus on innovation and a dedication to enhancing patient health, Revelation Biosciences, Inc. stands as a significant player in the biotech industry, promising solutions to some of the most challenging health conditions.
Revelation Biosciences Inc. (NASDAQ: REVB) reported its year-end 2022 financial results, showcasing a significant cash increase to $5.3 million, up from $1.3 million in 2021, primarily from a $15.6 million public offering. The company plans to initiate a combined Phase 1a clinical study for REVTx-100 and REVTx-300 in the latter half of 2023, supported by positive preclinical data. Revelation's net loss for 2022 was $10.8 million, or $20.09 per share, an improvement from $12.0 million in 2021, indicating reduced operational expenses. The firm anticipates sufficient funds to support operations through June 2024.
Revelation Biosciences Inc. (NASDAQ: REVB) has appointed Dr. Julia Bohannon and Dr. Antonio Hernandez to its Scientific Advisory Board. Dr. Bohannon, an Associate Professor at Vanderbilt University Medical Center, specializes in immunomodulatory treatments for burn injuries. Dr. Hernandez, also from Vanderbilt, focuses on enhancing innate immunity and developing therapies for critical care patients. Both bring significant expertise and will guide the company's PHAD-based technology for preventing and treating healthcare-associated infections. CEO James Rolke expressed excitement about their contributions to Revelation's ongoing efforts in immunologic therapies.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the closing of a public offering on February 13, 2023, raising approximately $15.6 million. The offering consisted of 2,888,600 common stock shares and 336,400 pre-funded warrants at $4.83 per share. Additionally, warrants to purchase up to 6,450,000 shares were included, with an exercise price of $5.36. The proceeds will fund clinical studies for REVTx-100 and REVTx-300, focusing on surgical site infections and acute kidney injury. The offering was made under registration statements declared effective on February 9, 2023, by the SEC.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a public offering of 3,225,000 shares priced at $4.83 each, along with warrants to purchase up to 6,450,000 additional shares at an exercise price of $5.36. The gross proceeds are expected to total approximately $15.6 million, intended for advancing the development of their therapies REVTx-100 and REVTx-300, including clinical trials and manufacturing. The offering is anticipated to close around February 13, 2023, pending usual conditions. Roth Capital Partners serves as the sole placement agent.
Revelation Biosciences Inc. (NASDAQ: REVB) reported statistically significant preclinical results for REVTx-300, a potential therapy for acute and chronic kidney disease. In a validated model, treatment with REVTx-300 led to significant reductions in TGF-β and increases in anti-inflammatory markers IL-10, hepcidin, and NGAL. No significant inflammation markers increased, indicating a potential reduction in fibrosis. The company plans to publish these findings in 2023 and is preparing to initiate clinical studies. Positive results were previously reported on October 25, 2022, and November 18, 2022, regarding renal fibrosis reduction.
Revelation Biosciences Inc. (NASDAQ: REVB) announced a 1-for-35 reverse stock split effective February 1, 2023, after stockholder approval. This action aims to increase the per-share market price to comply with NASDAQ's minimum bid requirements. Consequently, the outstanding shares will decrease to approximately 672,460 shares. Additionally, stockholders approved raising the authorized common stock to 500,000,000 shares and ratified Baker Tilly US, LLP as independent public accountants. The reverse split does not change stockholder equity proportions or the par value of the common stock.
Revelation Biosciences Inc. (NASDAQ: REVB) announced a mandatory separation of its trading units on January 13, 2023. Following this, units will cease to trade on the Nasdaq Capital Market. Each unit, consisting of one common stock share and one warrant priced at $11.50, will convert automatically into shares and warrants. Post-separation, common stock and warrants will trade under the symbols 'REVB' and 'REVBW'. Revelation focuses on immunologic therapies for disease prevention and treatment, with several candidates in development, including REVTx-100, REVTx-200, and REVTx-300.
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
What is Revelation Biosciences, Inc.?
What is the core technology of Revelation Biosciences, Inc.?
What are the primary programs based on the Gemini formulation?
What is the stock symbol for Revelation Biosciences, Inc.?
What diseases are targeted by Revelation Biosciences, Inc. products?
How does the Gemini formulation work?
Is Revelation Biosciences, Inc. conducting clinical trials?
What is the goal of Revelation Biosciences, Inc.?
Where can I find the latest news about Revelation Biosciences, Inc.?
What makes Revelation Biosciences, Inc. unique in the biotech industry?
